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There is accumulating evidence indicating that HDLs improve the functionality of 
pancreatic beta cells and the insulin sensitivity of peripheral tissues (e.g. skeletal 
muscle, liver). A very recent review [1] discusses the data supporting a protective role 
of HDLs in these tissues and the consequence that this may have on diabetes 
development. Oddly, this review does not mention the now amply demonstrated anti-
apoptotic function exerted by HDLs on pancreatic beta cells [2;3]. Since beta cell 
apoptosis contributes to the development of type 2 diabetes [4], understanding the 
pro-survival function of HDLs in beta cells is of particular importance. A study 
published a few months ago uncovered a link between HDL and the functionality of 
the endoplasmic reticulum (ER) in beta cells. This work shows that HDLs prevent 
beta cell death induced by various ER stressors, such as palmitate, ER overload, or 
the sarco-endoplasmic reticulum Ca2+-ATPase (SERCA) inhibitor thapsigargin, by 
maintaining the functionality of the ER in terms of protein folding and protein 
trafficking [●●5]. This is of interest because ER stress is a likely important contributor 
to the development of type 2 diabetes [6]. The beneficial role of HDLs on pancreatic 
beta cells can therefore be multiple. Firstly, by favoring their insulin secretory 
capacity, possibly via a concerted, still ill-defined, action on specific cholesterol 
transporters [7]. Secondly by decreasing the cholesterol load in beta cells, although it 
should not be forgotten that cholesterol levels need to be adequately maintained in 
the ER for proper insulin export in beta cells [8]. Thirdly by preserving the 
functionality of the ER [5]. This last effect, as mentioned above, appears to be 
required for the anti-apoptotic activity of HDLs against some ER stressors (e.g. 
palmitate) but should also help the beta cell synthesize and secrete insulin more 
efficiently. Most of the studies allowing these conclusions to be drawn do not provide 
mechanistic insights as to how this proceeds. The challenge in the field is now to 
identify the molecular players that mediate the beneficial effects of HDLs in beta 
cells. 
In beta cells, HDLs exert their protective functions independently of scavenger 
receptor class B, type I (SR-BI) [5;9]. In endothelial cells, in contrast, SR-BI mediates 
HDL signaling leading to Akt activation and eNOS stimulation [10;10], which is 
thought to mediate the beneficial effects of HDLs in these cells [11;12]. How HDLs 
mediate these signaling events had been unclear for many years. A logical possibility 
was that HDLs or HDL components directly activated SR-BI to stimulate its signaling 
activity. A series of elegant experiments using a point mutant of SR-BI that cannot 
interact with cholesterol in the plasma membrane [●●13] now indicate that this 
assumption was incorrect. What activates SR-BI signaling is a reduction in plasma 
membrane cholesterol levels. Hence, the ability of HDLs to activate SR-BI comes 
from their capacity to promote cholesterol efflux from the plasma membrane. 
Cholesterol efflux can be mediated when HDLs dock to SR-BI leading to SR-BI 
activation but it is not the docking per se that is involved in the stimulation of the 
receptor but rather the decrease in cholesterol in the vicinity of SR-BI [●●13]. The 
physiological function of the cholesterol sensing capacity of SR-BI will now need to 
be addressed and, in this context, generation of KI mice expressing the SR-BI 
receptor mutant that cannot sense plasma membrane cholesterol is eagerly awaited! 
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This work shows that the carboxy-terminal transmembrane segment of SR-BI, which has a 
cholesterol-binding capacity, is required for SR-BI’s ability to signal in response to HDLs (e.g. 
activation of eNOS in endothelial cells and stimulation of the p38 MAPK pathway in 
enterocytes). What this study convincingly demonstrates is that HDLs are not direct 
activators of SR-BI. They do stimulate the receptor though by inducing a local decrease in 
plasma membrane cholesterol that is then sensed by the carboxy-terminal transmembrane 
domain of SR-BI. This sensing leads to the stimulation of the receptor's signaling activity. 
Hence, this work provides key structural information on the signaling property of SR-BI and 
clarifies the role played by HDLs in this process. The new paradigm that this study 
establishes is that SR-BI monitors the extent of cholesterol depletion resulting, for example, 
from HDL-mediated efflux. Once the decrease in plasma membrane cholesterol reaches a 
certain threshold, SR-BI activates a series of signaling events that regulate various cell type-
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Belalcazar LM, Lang W, Haffner SM, Hoogeveen RC, Pi-Sunyer FX, Schwenke DC, Balasubramanyam A, 
Tracy RP, Kriska AP, Ballantyne CM: Adiponectin and the mediation of HDL cholesterol 
change with improved lifestyle: The Look AHEAD Study. J.Lipid.Res. 2012. 
Adiponectin is a hormone secreted by the adipose tissues that favors insulin 
sensitivity. The study by Belalcazar and colleagues now shows that adiponectin 
levels are significantly associated with HDL-C levels in individuals who are improving 
their lifestyle by decreasing caloric intake and by increasing physical activity (Look 
AHEAD study; see https://www.lookaheadtrial.org). Therefore, it appears that 
adiponectin levels are correlated with HDL levels in humans, confirming earlier data 
obtained in mice. The authors suggest that this association results from the capacity 
of adiponectin to increase the expression of proteins involved in HDL formation (e.g. 
ApoAI and ABCA1). With this interpretation, changes in HDL levels would be 
secondary to a rise in adiponectin levels. However, the reverse may just be as 
correct, i.e. increase in HDL levels leads to higher circulating adiponectin levels. This 
latter interpretation derives from the observation that increasing HDL levels by ApoAI 
infusion in mice led to an augmentation in circulating levels of adiponectin 
(Atherosclerosis 2010, 210:438-444). If this is what really happens, it would give 
HDLs another recognized means of exerting their beneficial action in humans: 
increasing circulating levels of adiponectin to favor insulin sensitivity. Whatever the 
reasons for the association of HDL and adiponectin levels in the blood, the study of 
Belalcazar and colleagues provides yet another good argument that lifestyle 
improvement brings tractable benefits to individuals. 
